Applied Genetic Technologies Corp (NASDAQ:AGTC) released its earnings data on 14 may Wednesday. The company reported ($25.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $25.08, American Banking and Market News reports. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.15 million.
Applied Genetic Technologies Corp (NASDAQ:AGTC) weekly performance is 49.55%. On last trading day company shares ended up $19.74. Analysts mean target price for the company is $22.75. Applied Genetic Technologies Corp (NASDAQ:AGTC) distance from 50-day simple moving average (SMA50) is 47.06%.
Analysts at Laidlaw initiated coverage on shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) in a research report issued to clients and investors on Monday. RXi Pharmaceuticals Corp (NASDAQ:RXII) shares advanced 5.95% in last trading session and ended the day on $2.85. RXII return on assets is -101.90%.RXi Pharmaceuticals Corp (NASDAQ:RXII) quarterly performance is -46.33%.
On June 2, 2014, TrovaGene Inc. (NASDAQ:TROV) issued a press release announcing that data from a study published in the 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology, demonstrates that oncogene mutation load in urinary cell-free DNA, as determined using the company’s precision cancer monitoring technology, is significantly correlated with treatment response. A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K. TrovaGene Inc. (NASDAQ:TROV) shares moved up 8.73% in last trading session and was closed at $4.11, while trading in range of $3.77 – $4.19. TrovaGene Inc. (NASDAQ:TROV) year to date (YTD) performance is -28.40%.
Vital Therapies, Inc. (NASDAQ:VTL), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, on 28 may announced financial results for the quarter ended March 31, 2014, and provided an update on recent operations. A net loss attributable to our common stockholders of $13.8 million. This compares to a net loss of $9.4 million and a net loss attributable to common stockholders of $10.3 million for the quarter ended March 31, 2013. Vital Therapies Inc. (NASDAQ:VTL) ended the last trading day at $12.70. Company weekly volatility is calculated as 7.17%. Vital Therapies Inc. (NASDAQ:VTL) showed a positive weekly performance of 1.20%.
Ignyta, Inc. (Nasdaq RXDX), an oncology precision medicine biotechnology company, announced on 31 may that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, were presented in an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Ignyta Inc. (NASDAQ:RXDX) weekly performance is 21.57%. On last trading day company shares ended up $8.34. Analysts mean target price for the company is $17.00. Ignyta Inc. (NASDAQ:RXDX) distance from 50-day simple moving average (SMA50) is 11.79%.